Distinctive patterns of microRNA expression in primary muscular disorders
The primary muscle disorders are a diverse group of diseases caused by various defective
structural proteins, abnormal signaling molecules, enzymes and proteins involved in …
structural proteins, abnormal signaling molecules, enzymes and proteins involved in …
[PDF][PDF] In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis
C Viscomi, E Bottani, G Civiletto, R Cerutti, M Moggio… - Cell metabolism, 2011 - cell.com
Increased mitochondrial biogenesis by activation of PPAR- or AMPK/PGC-1α-dependent
homeostatic pathways has been proposed as a treatment for mitochondrial disease. We tested …
homeostatic pathways has been proposed as a treatment for mitochondrial disease. We tested …
Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease
…, M Sciacco, D Ronchi, GP Comi, M Moggio… - Nature …, 2013 - nature.com
Known disease mechanisms in mitochondrial DNA (mtDNA) maintenance disorders alter
either the mitochondrial replication machinery (POLG, POLG2 and C10orf2) 1 , 2 , 3 or the …
either the mitochondrial replication machinery (POLG, POLG2 and C10orf2) 1 , 2 , 3 or the …
Cytochrome c Oxidase subunit I microdeletion in a patient with motor neuron disease
…, M Zeviani, L Napoli, N Bresolin, M Moggio… - Annals of …, 1998 - Wiley Online Library
An out‐of‐frame mutation of the mitochondrial DNA‐encoded subunit I of cytochrome c oxidase
(COX) was discovered during investigation of a severe isolated muscle COX deficiency …
(COX) was discovered during investigation of a severe isolated muscle COX deficiency …
Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1
D Gabellini, G D'Antona, M Moggio, A Prelle, C Zecca… - Nature, 2006 - nature.com
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant neuromuscular
disorder that is not due to a classical mutation within a protein-coding gene 1 , 2 . Instead, …
disorder that is not due to a classical mutation within a protein-coding gene 1 , 2 . Instead, …
[HTML][HTML] Histological effects of givinostat in boys with Duchenne muscular dystrophy
…, S Messina, GL Vita, B Gatti, M Moggio… - Neuromuscular …, 2016 - Elsevier
Duchenne Muscular Dystrophy (DMD) is caused by mutations in the dystrophin gene leading
to dystrophin deficiency, muscle fiber degeneration and progressive fibrotic replacement of …
to dystrophin deficiency, muscle fiber degeneration and progressive fibrotic replacement of …
Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical …
…, N Calvaresi, L Chiveri, A Prelle, M Moggio… - Journal of the …, 2001 - Elsevier
Overexpression of mutated superoxide dismutase (SOD1) in transgenic mice causes a
progressive motor neuron degeneration in the spinal cord similar to that in human amyotrophic …
progressive motor neuron degeneration in the spinal cord similar to that in human amyotrophic …
Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients
…, I Moroni, A Turconi, A Toscano, M Moggio… - Human …, 2008 - Wiley Online Library
Limb girdle muscular dystrophies (LGMD) are characterized by genetic and clinical
heterogeneity: seven autosomal dominant and 12 autosomal recessive loci have so far been …
heterogeneity: seven autosomal dominant and 12 autosomal recessive loci have so far been …
Phenotypic heterogeneity of the 8344A> G mtDNA “MERRF” mutation
Objectives: Myoclonic epilepsy with ragged-red fibers (MERRF) is a rare mitochondrial
syndrome, mostly caused by the 8344A>G mitochondrial DNA mutation. Most of the previous …
syndrome, mostly caused by the 8344A>G mitochondrial DNA mutation. Most of the previous …
Muscle coenzyme Q10 level in statin-related myopathy
…, V Lucchini, A Prelle, N Bresolin, M Moggio… - Archives of …, 2005 - jamanetwork.com
Background Statin drugs (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors)
reduce the level of cholesterol by inhibiting the synthesis of mevalonate, an intermediary in the …
reduce the level of cholesterol by inhibiting the synthesis of mevalonate, an intermediary in the …